Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arhalofenate - CymaBay Therapeutics

Drug Profile

Arhalofenate - CymaBay Therapeutics

Alternative Names: JNJ 39659100; K-118; MBX-102; Metaglidasen

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Amides; Anti-inflammatories; Antigouts; Antihyperglycaemics; Insulin sensitisers; Small molecules; Uricosurics
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2018 Kowa Pharmaceuticals terminates its licence agreement for the treatment of Gout in USA
  • 24 Jun 2018 Biomarkers information updated
  • 08 Jan 2018 CymaBay Therapeutics initiates a pharmacokinetic trial in subjects with renal impairment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top